Synthesis, In Vivo Anti-Inflammatory Activity, and Molecular Docking Studies of New Isatin Derivatives

Table 2

Showing the mean paw edema volume () for newly synthesized compounds (100 mg/kg bw) compared to standard drug indomethacin (10 mg/kg bw).

S. number	Compound (100 mg/kg)	1 hr	2 hr	3 hr	4 hr
1	Control	0.75 ± 0.05	0.82 ± 0.02	0.94 ± 0.09	1.2 ± 0.1
2	VIIa	0.65 ± 0.01	0.62 ± 0.05	0.58 ± 0.03	0.55 ± 0.01 (54)
3	VIIb	0.64 ± 0.08	0.61 ± 0.05	0.60 ± 0.01	0.57 ± 0.02 (52)
4	VIIc	0.55 ± 0.02	0.52 ± 0.04	0.48 ± 0.07	0.42 ± 0.01 (65)
5	VIId	0.58 ± 0.03	0.56 ± 0.09	0.50 ± 0.04	0.44 ± 0.08 (63)
6	VIIe	0.63 ± 0.05	0.61 ± 0.02	0.58 ± 0.04	0.54 ± 0.01 (55)
7	VIIf	0.60 ± 0.05	0.57 ± 0.08	0.55 ± 0.04	0.51 ± 0.03 (57)
8	VIIg	0.59 ± 0.01	0.56 ± 0.07	0.54 ± 0.03	0.50 ± 0.05 (58)
9	VIIh	0.69 ± 0.06	0.67 ± 0.02	0.64 ± 0.04	0.61 ± 0.01 (49)
10	VIIi	0.54 ± 0.03	0.52 ± 0.01	0.50 ± 0.08	0.45 ± 0.06 (62)
11	VIIj	0.52 ± 0.04	0.50 ± 0.08	0.46 ± 0.01	0.48 ± 0.02 (60)
12	Indomethacin (10 mg/kg)	0.51 ± 0.02	0.47 ± 0.09	0.42 ± 0.04	0.38 ± 0.01 (68)

All the values are expressed as mean ± SD (); , versus control.
Results in parenthesis are % of mean inhibition.